About Geneos Therapeutics
Geneos Therapeutics is a company based in Plymouth Meeting (United States) founded in 2016.. Geneos Therapeutics has raised $49.5 million across 5 funding rounds from investors including Korea Investment Holdings, Inovio Pharmaceuticals and Shanghai Healthcare Capital. The company has 7 employees as of December 31, 2020. Geneos Therapeutics offers products and services including PTCVs and GT-EPIC Platform. Geneos Therapeutics operates in a competitive market with competitors including argenx, MacroGenics, TScan Therapeutics, Lyell Immunopharma and Alexion, among others.
- Headquarter Plymouth Meeting, United States
- Employees 7 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Geneos Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$49.5 M (USD)
in 5 rounds
-
Latest Funding Round
$5 M (USD), Series A
Sep 28, 2023
-
Investors
Korea Investment Holdings
& 6 more
-
Employee Count
7
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Geneos Therapeutics
Geneos Therapeutics offers a comprehensive portfolio of products and services, including PTCVs and GT-EPIC Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Personalized DNA-based vaccines targeting tumor neoantigens for immunotherapy
Tool for designing custom cancer vaccines based on patient tumor mutations
Unlock access to complete
Unlock access to complete
Funding Insights of Geneos Therapeutics
Geneos Therapeutics has successfully raised a total of $49.5M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $5.0M
-
First Round
First Round
(21 Feb 2019)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Series A - Geneos Therapeutics | Valuation | Shanghai Healthcare Capital |
|
| Apr, 2023 | Amount | Series A - Geneos Therapeutics | Valuation | 3B Future Health Fund |
|
| Mar, 2022 | Amount | Series A - Geneos Therapeutics | Valuation | Flerie |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Geneos Therapeutics
Geneos Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Korea Investment Holdings, Inovio Pharmaceuticals and Shanghai Healthcare Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage healthcare investments are made by 3B Future Health Fund.
|
Founded Year | Domain | Location | |
|
Flerie is engaged in investing in biotech and pharmaceutical companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Geneos Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Geneos Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Geneos Therapeutics Comparisons
Competitors of Geneos Therapeutics
Geneos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, TScan Therapeutics, Lyell Immunopharma and Alexion, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Geneos Therapeutics
Frequently Asked Questions about Geneos Therapeutics
When was Geneos Therapeutics founded?
Geneos Therapeutics was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Where is Geneos Therapeutics located?
Geneos Therapeutics is headquartered in Plymouth Meeting, United States. It is registered at Plymouth Meeting, Pennsylvania, United States.
Is Geneos Therapeutics a funded company?
Geneos Therapeutics is a funded company, having raised a total of $49.5M across 5 funding rounds to date. The company's 1st funding round was a Series A of $17M, raised on Feb 21, 2019.
How many employees does Geneos Therapeutics have?
As of Dec 31, 2020, the latest employee count at Geneos Therapeutics is 7.
What does Geneos Therapeutics do?
Geneos Therapeutics was founded in 2016 and is headquartered in Plymouth Meeting, United States. Operations focus on the biotechnology sector, where tumor-specific neoantigen-targeted personalized immunotherapies are developed, including immune checkpoint inhibitors like anti-PD1PDL1 molecules. A proprietary design protected by patents supports the lead product, which is currently in phase III clinical trials for head and neck cancer, cervical dysplasia, and HIV. The companys domain is geneostx.com.
Who are the top competitors of Geneos Therapeutics?
Geneos Therapeutics's top competitors include argenx, Hummingbird Bioscience and Lyell Immunopharma.
What products or services does Geneos Therapeutics offer?
Geneos Therapeutics offers PTCVs and GT-EPIC Platform.
Who are Geneos Therapeutics's investors?
Geneos Therapeutics has 7 investors. Key investors include Korea Investment Holdings, Inovio Pharmaceuticals, Shanghai Healthcare Capital, 3B Future Health Fund, and Flerie.